Transient transfection of suspension cells is the most commonly used production platform for AAV manufacturing.

However, this method shows some limitations in large scale bioreactors: inadequate transfection protocol, reduced transfection efficiency and lower productivity. To address this concern, we present data on the novel transfection reagent showing: i) increased AAV titers, ii) improved transfection protocol for large scale bioreactors and iii) reproducibility of viral titers at different production scale.

Presented by Mathieu Porte, R&D Production  Manager at Polyplus-transfection®

Talk Available on demande on the In Vivo Gene Therapy track for the duration of the virtual event